Gauthier O, Bouler J M, Aguado E, Legeros R Z, Pilet P, Daculsi G
Laboratoire de Chirurgie, Ecole Nationale Vétérinaire de Nantes, Route de Gachet, BP 40706, 44307 Nantes Cedex 3, France.
J Mater Sci Mater Med. 1999 Apr;10(4):199-204. doi: 10.1023/a:1008949910440.
Two different preparations of biphasic calcium phosphate (BCP) were characterized in vitro: BCP1 from a mechanical mixture of hydroxyapatite (HA) and beta-tricalcium phosphate (beta-TCP) powders, and BCP2 from calcination of a calcium-deficient apatite (CDA). The structural, physicochemical and mechanical parameters of these two preparations were investigated, and two different macroporous BCP1 (MBCP1) and BCP2 MBCP2) implants were manufactured and implanted in rabbit bone for in vivo bioactivity studies. Scanning electron microscopy observations showed that MBCP1 implants had a significantly higher degradation rate (P<0.0001) than MBCP2 implants. This was probably caused by the presence of calcium oxide impurities in BCP1 and the more intimate mixture and stable ultrastructure of BCP2. No significant difference about the newly formed bone rate in these two BCP preparations was observed. Very slight variations in sintering conditions appeared to influence the biodegradation behavior of the two MBCP implants despite their identical HA/-TCP ratios and similar porosity. Precise and complete in vitro characterization enabled us to understand and predict in vivo degradation behavior.
对两种不同的双相磷酸钙(BCP)制剂进行了体外表征:BCP1由羟基磷灰石(HA)和β-磷酸三钙(β-TCP)粉末的机械混合物制成,BCP2由缺钙磷灰石(CDA)煅烧制成。研究了这两种制剂的结构、物理化学和力学参数,并制造了两种不同的大孔BCP1(MBCP1)和BCP2(MBCP2)植入物,将其植入兔骨中进行体内生物活性研究。扫描电子显微镜观察表明,MBCP1植入物的降解率显著高于MBCP2植入物(P<0.0001)。这可能是由于BCP1中存在氧化钙杂质以及BCP2更紧密的混合物和稳定的超微结构所致。在这两种BCP制剂中,未观察到新形成骨率的显著差异。尽管两种MBCP植入物的HA/TCP比率相同且孔隙率相似,但烧结条件的非常轻微变化似乎影响了它们的生物降解行为。精确而完整的体外表征使我们能够理解和预测体内降解行为。